Wish4Life Foundation, a US-based non-government organisation (NGO) dedicated to the care of children battling with cancer, is ...

Government funding will support 250 jobs in health-care technology at a Mississauga-based company. Hoffman-La Roche Limited’s ...

Wish4Life Foundation, a U.S.A based non-government organisation (NGO) dedicated to the care of children battling with cancer, ...

The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

These jobs will propel the province towards being a global leader in biomanufacturing and life sciences. MISSISSAUGA, ON, Nov ...

AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...

Neuron23 unveiled details around its global Phase 2 NEULARK clinical trial of NEU-411 in people with early Parkinson’s disease.

Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...

The Executive Vice-President, Diagnostics, Africa at Roche Diagnostics, Dr. Allan Pamba stated this in a statement to ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

Executive Vice-President of Diagnostics, Africa, at Roche Diagnostics, Dr. Allan Pamba, has urged action against diabetes. He said November is World Diabetes Awareness month, noting non-communicable ...

NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...